abemaciclib (Verzenio)
Jump to navigation
Jump to search
Indications
- early breast cancer in certain patients*[4]
- ER+, HER2- metastatic breast cancer
* high-risk, node-positive with a Ki-67 score of > 19[4]
Dosage
- 200 mg BID
- 150 mg BID in combination with fulvestrant
- fulvestrant dose is 500 mg IM on days 1, 15, & 29, & once monthly thereafter[3]
Tabs: 50 mg, 100 mg, 150 mg, & 200 mg
Pharmacokinetics
- metabolized by CYP3A
Adverse effects
- diarrhea, nausea, vomiting, abdominal pain, decreased appetite
- leukopenia, neutropenia, thrombocytopenia, anemia
- infections
- fatigue, headache
Mechanism of action
More general terms
References
- ↑ Wikipedia: Abemaciclib https://en.wikipedia.org/wiki/Abemaciclib
- ↑ Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm - ↑ 3.0 3.1 Dickler MN, Tolaney SM, Rugo HS et al MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017 Sep 1;23(17):5218-5224. Epub 2017 May 22. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28533223
Sledge GW Jr, Toi M, Neven P et al MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017 Sep 1;35(25):2875-2884. Epub 2017 Jun 3. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28580882 - ↑ 4.0 4.1 4.2 Chustecka Z New Approval in Early Breast Cancer: First Advance in 20 Years. Medscape. October 13, 2021 https://www.medscape.com/viewarticle/960784
- ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION. VERZENIO https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716s000lbl.pdf